Aquestive Therapeutics (AQST) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings or view top-rated stocks.

4 analysts have issued 1-year price targets for Aquestive Therapeutics' shares. Their AQST share price forecasts range from $4.00 to $8.50. On average, they predict the company's stock price to reach $6.13 in the next twelve months. This suggests a possible upside of 197.3% from the stock's current price.
View analysts price targets for AQST or view top-rated stocks among Wall Street analysts.

Aquestive Therapeutics' stock was trading at $0.9021 at the start of the year. Since then, AQST shares have increased by 128.4% and is now trading at $2.06.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our AQST earnings forecast.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) released its earnings results on Wednesday, March, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The company had revenue of $10.68 million for the quarter, compared to analyst estimates of $9.93 million. During the same quarter last year, the firm earned ($0.38) EPS.

Aquestive Therapeutics updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $42.00 million-$46.00 million, compared to the consensus revenue estimate of $39.06 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Aquestive Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vahanian & Associates Financial Planning Inc. (1.29%), Renaissance Technologies LLC (0.93%), Susquehanna International Group LLP (0.21%), HBK Sorce Advisory LLC (0.15%), Financial Advocates Investment Management (0.04%) and Jane Street Group LLC (0.04%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, John T Maxwell, Keith J Kendall, Lori J Braender and Peter E Boyd.
View institutional ownership trends.

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AQST stock can currently be purchased for approximately $2.06.

Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $115.20 million and generates $46.54 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

The company employs 157 workers across the globe.

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com.